DSpace Repository

Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Show simple item record

dc.contributor.author Salazar, C.A.
dc.contributor.author Málaga Rodríguez, Germán Javier
dc.contributor.author Malasquez, G.
dc.contributor.author Bernardo, R.
dc.date.accessioned 2019-02-22T14:56:09Z
dc.date.available 2019-02-22T14:56:09Z
dc.date.issued 2015
dc.identifier.uri https://hdl.handle.net/20.500.12866/5848
dc.description.abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus low molecular weight heparins in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. To examine the existing clinical evidence on the efficacy of prophylactic anticoagulation with direct factor Xa inhibitors versus vitamin K antagonists, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. To evaluate the existing clinical evidence on the risks including any adverse event (serious or not) of bleeding, skin necrosis, heparin‐induced thrombocytopenia or hepatopathy associated with the analyzed therapies, in the prevention of venous thromboembolism in patients who have undergone total hip or knee replacement or hip fracture repair. en_US
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartofseries Cochrane Database of Systematic Reviews
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject human en_US
dc.subject Article en_US
dc.subject chemoprophylaxis en_US
dc.subject priority journal en_US
dc.subject drug efficacy en_US
dc.subject bleeding en_US
dc.subject venous thromboembolism en_US
dc.subject anticoagulant therapy en_US
dc.subject warfarin en_US
dc.subject adverse event en_US
dc.subject antivitamin K en_US
dc.subject blood clotting factor 10a inhibitor en_US
dc.subject elective surgery en_US
dc.subject fondaparinux en_US
dc.subject fracture treatment en_US
dc.subject heparin induced thrombocytopenia en_US
dc.subject hip fracture en_US
dc.subject hip replacement en_US
dc.subject idraparinux en_US
dc.subject knee replacement en_US
dc.subject liver disease en_US
dc.subject low molecular weight heparin en_US
dc.subject skin necrosis en_US
dc.title Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1002/14651858.CD011762
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.05
dc.relation.issn 1469-493X


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics